(-)-p-Chloroamphetamine hydrochloride | 16064-31-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (-)-p-Chloroamphetamine hydrochloride
• 英文别名: (2R)-1-(4-chlorophenyl)propan-2-amine;hydrochloride
• CAS: 16064-31-6
• 化学式: C9H13Cl2N
• 分子量: 206.11
• InChiKey: DZAANUYJOGCNLL-OGFXRTJISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.65
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• [EN] PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES<br/>[FR] DERIVES AZABICYCLIQUES DE PYRIDYLOXYMETHYL ET DE BENZISOXAZOLE
  申请人：PFIZER PROD INC

  公开号：WO2004081007A1

  公开（公告）日：2004-09-23

  An aminomethylpyridyloxymethyl/benzisoxazole substituted azabicyclic compound according to formula (I) a pharmaceutical composition comprising same, and a method of treating one or more CNS or other disorders, including concurrent treatment of disorders such as chizophrenia and depression. Or the (R) or (S) enantiomer thereof, or the cis or trans isomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or of any of the foregoing, wherein m is 0 or 1, Z is wherein R7 is hydrogen or (C1-C3)alkoxy; R8 is hydrogen, hydroxy, or (C1-C3)alkoxy; and R9 is (C1-C3)alkoxy; X is oxygen or NR, wherein R is hydrogen or (C1-C6)alkyl; Y is methylene, wherein n is 0, 1 or 2; or oxygen, nitrogen or sulfur, wherein n is 2, 3 or 4; R1 and R2 are each independently hydrogen, halogen, or a (C1-C6)alkyl, (C1-C6)alkoxy or a (C1-C6)alkoxy(C1-C6)alkyl group, any one of which groups may be unsbustituted or substituted with one or more halogens.

  根据公式（I），一种含有氨甲基吡啶氧甲基/苯并异噁唑取代的氮杂环化合物，包括相同的药物组合物，以及治疗一种或多种中枢神经系统或其他疾病的方法，包括同时治疗精神分裂症和抑郁症等疾病。或其（R）或（S）对映体，或其顺式或反式异构体，或其药用可接受的盐、溶剂化合物或前药，或前述任何一种，其中m为0或1，Z为其中R7为氢或（C1-C3）烷氧基；R8为氢、羟基或（C1-C3）烷氧基；R9为（C1-C3）烷氧基；X为氧或NR，其中R为氢或（C1-C6）烷基；Y为亚甲基，其中n为0、1或2；或氧、氮或硫，其中n为2、3或4；R1和R2各自独立地为氢、卤素或（C1-C6）烷基，（C1-C6）烷氧基或（C1-C6）烷氧基（C1-C6）烷基基团，其中任何一个基团可以未被取代或被一个或多个卤素取代。
• Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
  申请人：——

  公开号：US20030073842A1

  公开（公告）日：2003-04-17

  The invention is directed to substituted benzimidazol-2-ones of Formula I, 1 wherein A, X, Y, m, n, R 1 , R 2 , R 3 , R 4 , and R 5 are as described in the specification, which are useful as vasopressin receptor antagonists or Neuropeptide Y Modulators for treating conditions such as aggression, obsessive-compulsive disorders, hypertension, dysmenorrhea, congestive heart failure/cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, edema, ischemia, stroke, thrombosis, water retention, nephrotic syndrome, central nervous injuries, obesity, anorexia, hyperglycemia, diabetes, anxiety, depression, asthma, memory loss, sexual dysfunction, disorders of sleep and other circadian rhythms, and Cushing's disease.

  该发明涉及Formula I的取代苯并咪唑酮，其中A、X、Y、m、n、R1、R2、R3、R4和R5如说明书中所述，其可用作抗利尿素受体拮抗剂或神经肽Y调节剂，用于治疗侵略性、强迫症障碍、高血压、痛经、充血性心力衰竭/心脏不全、冠状动脉痉挛、心肌缺血、肝硬化、肾血管痉挛、肾功能衰竭、水肿、缺血、中风、血栓形成、水潴留、肾症候群、中枢神经损伤、肥胖、厌食、高血糖、糖尿病、焦虑、抑郁、哮喘、记忆丧失、性功能障碍、睡眠障碍和其他生物钟紊乱症状，以及库欣综合征。
• [EN] NK1 ANTAGONIST<br/>[FR] ANTAGONISTE DE NK1
  申请人：PFIZER PROD INC

  公开号：WO2004110996A1

  公开（公告）日：2004-12-23

  The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-meditated conditions.Formula (I)

  这项发明涉及一种具有神经激肽抑制作用的化合物，包括该化合物的药物组合物以及用于神经激肽介导疾病的治疗方法。公式（I）
• [EN] QUINOLINE DERIVATIVES<br/>[FR] DERIVES QUINOLINIQUES
  申请人：PFIZER PROD INC

  公开号：WO2004043929A1

  公开（公告）日：2004-05-27

  The present invention relates to compounds of Formula I, wherein R1, R2, R3, R4, and n are as defined, and to pharmaceutically acceptable salts of said compounds. Compounds of Formula I have activity in agonizing 5HT7 receptors and are useful in treating, for example, disorders that can be treated by modulating circadian rhythms.

  本发明涉及式I的化合物，其中R1、R2、R3、R4和n如定义所述，并且涉及所述化合物的药用可接受的盐。式I的化合物在激活5HT7受体方面具有活性，并且可用于治疗例如可以通过调节昼夜节律来治疗的疾病。
• 5HT7 Antagonists and inverse agonists
  申请人：Pfizer Inc.

  公开号：US20040229874A1

  公开（公告）日：2004-11-18

  The present invention relates to compounds of formula I, 1 and the pharmaceutically acceptable salts thereof. These compounds are useful as psychotherapeutic agents.

  本发明涉及公式I的化合物及其药用盐。这些化合物可用作心理治疗药物。